Haier Biomedical

Impact: Haier Biomedical showcased its full-scenario laboratory solutions at analytica 2026, highlighting its deepening localization strategy and product innovations, which is expected to strengthen its market position in Europe.

Impact: Haier Biomedical launched new automated low-carbon cold storage products at two major global trade fairs, strengthening its global market presence and demonstrating its commitment to localized innovation and service.

Impact: Haier Biomedical released its 2025 Sustainability Report, showcasing significant progress in environmental, social, and governance initiatives, technological innovation, and global health accessibility, which positively impacts its reputation and market standing.

Impact: Haier Biomedical achieved a double No. 1 ranking in global and overseas sales for life science laboratory equipment, according to Euromonitor International, confirming its market leadership and successful international expansion. This positive recognition is expected to boost its reputation and potentially its stock performance.

Impact: Haier Biomedical is the main actor, presenting its digital blood management platform and accelerating its transformation to a full-process solution provider.

Impact: Haier Biomedical is the maker of the Sweden — Stockholm test and is actively pursuing FDA approval for its use in routine screening in the United States. The positive study results are crucial for its commercialization efforts.

Impact: Haier Biomedical continues to deliver key overseas projects, such as the UK Biobank, and holds the No. 1 market share in seven countries.